Baseline characteristics of men (n=623) receiving primary treatment for prostate cancer and with multiple prostate-specific antigen (PSA) tests
| Characteristics | Surgery (n=225) | Radiation (n=398) | P value | Total (n=623) |
| Age (years) | <0.001 | |||
| 50–59 | 19 (8.4%) | 8 (2.0%) | 27 (4.3%) | |
| 60–69 | 143 (63.6%) | 134 (33.7%) | 277 (44.5%) | |
| 70–79 | 63 (28.0%) | 242 (60.8%) | 305 (49.0%) | |
| ≥80 | 0 (0%) | 14 (3.5%) | 14 (2.2%) | |
| Race | 0.83 | |||
| Black | 27 (12%) | 42 (10.6%) | 69 (11.1%) | |
| White | 198 (88%) | 356 (89.4%) | 554 (88.9%) | |
| Comorbidity (Charlson) | <0.001 | |||
| 0 (none) | 91 (40.4%) | 103 (25.9%) | 194 (31.1%) | |
| 1 (mild) | 70 (31.1%) | 131 (32.9%) | 201 (32.3%) | |
| 2 (moderate) | 47 (20.9%) | 93 (23.4%) | 140 (22.5%) | |
| 3 (severe) | 17 (7.7%) | 71 (17.8%) | 88 (14.1%) | |
| Anatomic stage | 0.04 | |||
| Localized | 221 (98.2%) | 374 (94.0%) | 595 (95.5%) | |
| Regional | 4 (1.8%) | 24 (6.0%) | 28 (4.5%) | |
| Histologic grade | 0.046 | |||
| Well | 57 (25.3%) | 81 (20.4%) | 138 (22.2%) | |
| Moderate | 147 (65.3%) | 254 (63.8%) | 401 (64.4%) | |
| Poor | 21 (9.4%) | 63 (15.8%) | 84 (13.5%) | |
| Baseline PSA (ng/mL) | <0.001 | |||
| 0 to <4.0 | 39 (17.3%) | 38 (9.5%) | 77 (12.4%) | |
| 4.0 to <10.0 | 105 (46.7%) | 157 (39.5%) | 262 (42.1%) | |
| 10.0 to <20.0 | 49 (21.8%) | 118 (29.6%) | 167 (26.8%) | |
| ≥20.0 | 29 (12.9%) | 84 (21.1%) | 113 (18.1%) | |
| Unknown | 3 (1.3%) | 1 (0.3%) | 4 (0.6%) |